Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 35Plasma cell 33Other hematologic neoplasm 7Thoracic 1Sarcoma 1Myeloid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1

Interventions

Docetaxel 8pembrolizumab 7Pemetrexed 5Carboplatin 5Erlotinib Hydrochloride 4toripalimab 3rociletinib 3fludarabine 3Radiosurgery 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Gemcitabine 3Etoposide 3Cyclophosphamide 3Cisplatin 3Bevacizumab 3lorlatinib 2atezolizumab 2Vinorelbine 2Topotecan 2Radiotherapy 2Platinum 2Itraconazole 2Irinotecan 2Interleukin-2 2Cetuximab 2Albumin-Bound Paclitaxel 2vinflunine 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Lenalidomide × Thoracic × Clear all
NCT02963610 2021-12-30

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

Fox Chase Cancer Center

Phase 1/2 Terminated
3 enrolled 5 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡